Mechelen, Belgium; 23 March 2017 - Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016.
The annual report for the financial year 2016, including a review of figures and performance, is available online on http://reports.glpg.com/annual-report-2016/nl/ and can also be downloaded as PDF.
Furthermore, Galapagos has the honor to invite its shareholders, warrant holders, directors and statutory auditor to its annual and extraordinary shareholders’ meetings that will be held on Tuesday 25 April 2017 at 2:00 p.m. (CET) at the registered office of the Company.
In order to be admitted to the shareholders’ meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code and article 29 of the Company’s articles of association, and fulfill the formalities described in the convening notice. The convening notice and other documents pertaining to the shareholders’ meetings can be consulted on our website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 510 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
Investors:
Elizabeth Goodwin
VP IR & Corporate
Communications
+1 781 460 1784
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir@glpg.com
